MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...
Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination regimen used ...
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Looking to move up in your current job or change careers? Try a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback